Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2012 Financial Results
Date:3/11/2013

in research and development expenses related to the Zerenex clinical program.  The net loss for the fourth quarter ended December 31, 2012, included $0.5 million of non-cash compensation expense related to equity incentive grants.

The net loss for the year ended December 31, 2012, was $22.7 million, or $0.32 per share, compared to a net loss of $28.1 million, or $0.42 per share, for the year ended December 31, 2011, representing a decrease in net loss of $5.4 million.  The change in net loss in the year ended December 31, 2012, as compared to 2011, was primarily attributable to an $8.9 million decrease in research and development expenses due to the cessation of the development of KRX-0401 (perifosine) in May 2012, partially offset by a $2.5 million increase in research and development expenses related to the Zerenex clinical program.  The net loss for the year ended December 31, 2011, included license revenue of $5.0 million related to a milestone payment from JT and Torii for their commencement, in April 2011, of a Phase 3 clinical program in Japan.  The net loss for the year ended December 31, 2012, included a non-cash extraordinary gain of $2.6 million related to a write-off of the contingent equity rights liability following the termination of the license agreement for KRX-0401 in May 2012 and $2.2 million of non-cash compensation expense related to equity incentive grants. 

Ron Bentsur , the Company's Chief Executive Officer, commented, "In January, we reached a major milestone with the announcement of successful top-line results from the long-term Phase 3 study of Zerenex.  Following that announcement, we solidified our balance sheet with a substantial capital raise, allowing us to focus on the next key milestones for the Company, specifically, our pending U.S. New Drug Application and European Marketing Authorization Application filings and a potential launch for Zerenex in the middl
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Fourth Quarter and Year-End 2012 Financial Results
2. Keryx Biopharmaceuticals to Present at the Citigroup 2013 Global Healthcare Conference
3. Keryx Biopharmaceuticals Announces Pricing of Public Offering of Common Stock
4. Keryx Biopharmaceuticals Announces $55 Million Proposed Public Offering of Common Stock
5. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Third Quarter 2012 Financial Results
6. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Second Quarter 2012 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
8. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
9. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
10. Par Pharmaceutical Announces Quarterly Conference Call
11. HeartWare International, Inc. Announces Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  The Chemistry, Food ... Ministry of Health approved the introduction of Telaprevir ... the cure rate from Hepatitis C, and it ... 1 virus. Telaprevir is available in ... Photo - http://www2.prnewswire.com.br/imgs/pub/2014-07-25/original/2026.jpg   ...
(Date:7/25/2014)... July 25, 2014  Solanbridge Group Inc (OTC: SLNX) ... majority interest in Buzznbrewz.com and the Letter of Intent ... a fully executed Purchase Agreement. Charles ... are proud to have Mr. David Pecoraro ... experience in the private sector and developed a tremendous ...
(Date:7/25/2014)... July 25, 2014 Research and Markets ... Ophthalmic Diagnostic Devices Market 2014-2018" report to their ... About Ophthalmic Diagnostic Device An ... identify a defect or deficiency in the human visual ... disorders such as presbyopia, cataracts, glaucoma, retinal disorders, conjunctivitis, ...
Breaking Medicine Technology:The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3Solanbridge Group Inc Announces Acquisition of Buzznbrewz.com 2Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2
... Results of Largest Randomized, Placebo-controlled Trial,Ever Conducted ... of,Clinical Oncology, CHICAGO, June 04, 2007 /PRNewswire/ ... clinical trial ever,conducted in patients with cutaneous ... than twice as effective as placebo in ...
... in Patients With Follicular Lymphoma Reported,Today at ... /PRNewswire/ -- GlaxoSmithKline plc,announced today long-term efficacy ... a,single one-week course of frontline treatment with ... Tositumomab) in,76 patients with newly diagnosed advanced ...
Cached Medicine Technology:Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 2Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 3Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 4Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 5Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 68-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 28-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 38-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 48-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 58-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 68-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 7
(Date:7/28/2014)... 2014 Scientists in Japan have completed ... blood test for the asbestos cancer mesothelioma. Surviving Mesothelioma ... Click here to read it now. , ... Juntendo University Graduate School of Medicine say a new ... step above the old test. , “Particularly for ...
(Date:7/28/2014)... July 28, 2014 Maternal and Family ... Tucker Award, which will be presented at the agency’s ... October 29th at the Westmoreland Club in Wilkes-Barre. , ... Commissioner and long-time employee of MFHS. She dedicated ... political activist, health advocate, and champion for women, children ...
(Date:7/28/2014)... that following a healthy lifestyle may lower childhood cancer ... online in CANCER , a peer-reviewed journal of ... with cancer and adults who had cancer when they ... may influence their long-term health. , Adults who ... increased risk for the metabolic syndrome, a group of ...
(Date:7/28/2014)... As health insurers design their strategies ... exchanges. “Private Exchange Strategies for Insurers: What’s Working? ... Information Services, will provide answers to the big-dollar questions ... future. , Barbara Gniewek, Jonathan Har-Even and Martin Hill ... the private exchange sector — will provide expert presentations ...
(Date:7/28/2014)... GA (PRWEB) July 28, 2014 Mitul ... the nation gathered at the MGE Management Experts Benefit ... and community leaders joined the Dentists to raise funds ... the Boys and Girls Clubs and Youth Programs across ... of young people with books and audio books to ...
Breaking Medicine News(10 mins):Health News:Test Results Look Promising for New Mesothelioma Blood Test, According to Surviving Mesothelioma 2Health News:MFHS Seeking Nominations for Rose Allan Tucker Award 2Health News:Lifestyle choices may affect the long-term heart health of childhood cancer survivors 2Health News:Three PwC Consultants to Offer Insurers Successful Strategies for Private Exchanges 2Health News:Mitul R. Patel, DDS Successfully Attacks a Major Source of Economic Destruction in the Battle Against Illiteracy and Poverty 2Health News:Mitul R. Patel, DDS Successfully Attacks a Major Source of Economic Destruction in the Battle Against Illiteracy and Poverty 3
... Results from two,studies comparing colorectal cancer screening ... called virtual colonoscopy),have sparked interest in colorectal cancer ... consumers. The studies, one a large multi-center,trial sponsored ... other from the,University of Wisconsin published in the ...
... Health COO First Annual Honoree, SOMERSET, N.J., Oct. ... (Nasdaq: VTIV ) and President and CEO,of inVentiv ... Big,Brothers Big Sisters(R) (BBBS) of Hunterdon & Somerset Counties ... Moments, Big Magic -- A,Match That Lights an Eternal ...
... Liver, NEW YORK, Oct. 5 Urging every ... (ALF) today observed Liver,Awareness Month by releasing 12 tips ... Liver disease, a serious and largely unrecognized problem in ... among adults between the ages of,25 and 64, taking ...
... month a collaboration of European and Asian researchers launched ... harnessing the combined power of more than 40,000 computers ... drug discovery. , Called Enabling Grids for E-sciencE, the ... supercomputer that is being used during this challenge to ...
... Tenn., Oct. 5 Emdeon Business Services,announced ... Delta Dental payers for,insurance eligibility and benefits ... vendor partners and through the Emdeon suite ... Provider Services,(DPS), Emdeon,s interactive web portal. Emdeon ...
... Mich., Oct. 5 Volkswagen of America,Inc., in ... Volkswagen,dealers, proudly announces its 12th consecutive year of ... delighted to continue our sponsorship for our 12th ... "The LaSalle Bank,Chicago Marathon is a great opportunity ...
Cached Medicine News:Health News:Frequently Asked Questions When Considering a Colorectal Cancer Screening Test, From the American College of Gastroenterology 2Health News:Frequently Asked Questions When Considering a Colorectal Cancer Screening Test, From the American College of Gastroenterology 3Health News:Terrell Herring Honored by Big Brothers Big Sisters 2Health News:October is Liver Awareness Month: The American Liver Foundation Urges All Americans to Pay Attention to Their Liver Every Day of the Year 2Health News:October is Liver Awareness Month: The American Liver Foundation Urges All Americans to Pay Attention to Their Liver Every Day of the Year 3Health News:Grid computing offers new hope in race against bird flu 2Health News:Emdeon Business Services Extends Market Leadership With New Dental Eligibility Payers 2Health News:Volkswagen Continues Sponsorship of the Lasalle Bank Chicago Marathon 2
... PROXIMATE Access 55 Articulating Linear Staplers are ... or a thick-tissue green instrument (non-reloadable). Each ... 55mm staple line., ,Benefits include: , ... in narrow male pelvis. , Articulating head ...
... Staplers deliver two staggered rows of titanium staples ... be reloaded up to three times for a ... wire staples for thick tissue. The TLV model ... ,Benefits include: , Parallel jaw closure ensures that ...
... Loading Units With Titanium Staples ... TA™ (Single Use Reloadable Stapler ... Auto Suture™ PREMIUM MULTIFIRE TA™ ... gynecological, pediatric and thoracic surgical ...
Single Use Reloadable Stapler with Titanium Staples., ,The Auto Suture™ PREMIUM MULTIFIRE TA™ stapler has applications in abdominal, gynecological, pediatric and thoracic surgical proced...
Medicine Products: